Skip to main content
Winner Medical Co., Ltd. logo

Winner Medical Co., Ltd. — Investor Relations & Filings

Ticker · 300888 ISIN · CNE1000047Z8 LEI · 3003001HWYP0KVG4J717 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2026-05-22 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300888

About Winner Medical Co., Ltd.

https://www.winnermedical.com

Winner Medical Co., Ltd. specializes in the research, development, manufacturing, and distribution of cotton-based medical dressings and consumer health products. The company operates through two primary segments: medical supplies and consumer goods. Its medical portfolio includes high-quality wound care products, surgical kits, and infection prevention supplies such as masks and protective gowns. Under its PurCotton brand, the company produces a wide range of consumer items, including cotton tissues, feminine care products, and baby care essentials, utilizing proprietary non-woven cotton technology. Winner Medical emphasizes the use of natural materials to provide safe, comfortable, and environmentally friendly solutions. The company maintains a vertically integrated supply chain and adheres to international quality standards, serving healthcare institutions and retail markets worldwide with a focus on hygiene and skin-friendly applications.

Recent filings

Filing Released Lang Actions
关于调整2024年限制性股票激励计划授予价格的公告
Share Issue/Capital Change Classification · 65% confidence The document is a corporate announcement detailing adjustments to the grant price of a 2024 restricted stock incentive plan due to an equity distribution, including board approvals and the price formula. This is not an earnings release, legal report, or management discussion, but rather a notice of a capital change relating to employee share issuance under a stock incentive plan. Accordingly, it best fits the Share Issue/Capital Change category.
2026-05-22 Chinese
2025年年度报告（英文版）
Annual Report Classification · 95% confidence The document is titled ‘2025 ANNUAL REPORT’ and contains a full Letter to Shareholders, detailed sections including Management Discussion and Analysis, ESG, financial statements, audit opinions, and comprehensive corporate information. It represents the company’s official yearly report covering business activities and full financial performance for the fiscal year. Therefore, it is classified as an Annual Report. FY 2025
2026-05-22 English
广东崇立律师事务所关于稳健医疗用品股份有限公司2024年限制性股票激励计划授予价格调整、首次授予部分第一个归属期归属条件成就及部分限制性股票作废相关事项的法律意见书
Regulatory Filings Classification · 80% confidence The document is a legal opinion letter (“法律意见书”) from Chong Li Law Firm concerning adjustments, vesting conditions, and cancellations under the company’s 2024 restricted stock incentive plan. It contains legal analysis, procedural approvals, and counsel conclusions, but no substantive financial statements, earnings metrics, or investor presentation material. It is not an Annual Report, Interim Report, Audit Report, Earnings Release, or any other narrowly defined category. As a standalone legal opinion/compliance document that does not neatly fit other categories, it falls into the fallback “Regulatory Filings” category (RNS).
2026-05-22 Chinese
关于调整回购股份资金来源的公告
Transaction in Own Shares Classification · 90% confidence The document is an official announcement regarding adjustments to the company’s share repurchase plan (回购股份) – specifically changing the source of funds for its buyback program. It details the board resolution, repurchase price limits, total amounts, timelines, and the procedural approvals for the share buyback. This falls squarely under “Transaction in Own Shares (share repurchase/issuance)” rather than a dividend, financing, or general regulatory notice.
2026-05-22 Chinese
关于作废2024年限制性股票激励计划部分已授予但尚未归属的限制性股票的公告
Share Issue/Capital Change Classification · 75% confidence The document is a corporate announcement by a listed Chinese company (证券代码 300888) regarding the cancellation of 2,633,320 shares under its 2024 restricted stock incentive plan. It details the board approvals, legal opinions, and compliance with regulations. This is not an earnings release, earnings call transcript, audit report, or management change notice. It is a corporate action affecting the share capital (cancellation of unvested restricted shares), which falls under Share Issue/Capital Change (SHA).
2026-05-22 Chinese
董事会薪酬与考核委员会关于2024年限制性股票激励计划授予价格调整、首次授予部分第一个归属期归属名单及作废部分已授予但尚未归属的限制性股票的核查意见
Share Issue/Capital Change Classification · 85% confidence The document is the Board’s Compensation and Assessment Committee’s formal opinions (核查意见) regarding adjustments to the grant price, vesting list for the first tranche, and cancellation of part of the granted but unvested restricted stock under the company’s 2024 equity incentive plan. This is an announcement of a new share issuance event (restricted stock grants and cancellations) and fits best under “Share Issue/Capital Change.”
2026-05-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.